FDA Issues Draft Guidance on MRD Testing.
Experts from industry and academia welcomed new draft guidelines from the FDA on how best to use minimal residual disease (MRD) testing as a surrogate endpoint in blood cancer trials. However, they called for more guidance on the technological aspects of MRD testing.